Is metabolic dysfunction-associated fatty liver disease (MAFLD) associated with systemic atherosclerosis?
MAFLD and its subtypes are associated with increased systemic atherosclerosis, suggesting fatty liver disease may be a target for intervention to reduce cardiovascular risk.
MAFLD and its subtypes of DM-MAFLD and OW-MAFLD were associated with the extent of atherosclerotic plaques and stenosis, and presence of PolyVD. This study implicated that FLD might be a potential target of intervention for reducing the deleterious effects of MAFLD on systemic atherosclerosis.
Zhang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: